2006, Number 1
<< Back Next >>
Rev Gastroenterol Mex 2006; 71 (1)
Evaluation of high sensitivity Creactive protein (hsCRP) as a mar ker of hepatic inflammation in patients with metabolic syndrome
Rodríguez-Leal GA, Morán S, Gallardo I, Milke P, Guevara-González L
Language: Spanish
References: 31
Page: 39-45
PDF size: 69.91 Kb.
ABSTRACT
C-reactive protein (CRP) plays an important role on inflammatory processes associated to the metabolic syndrome (MS), alike of insulin sensitivity, endothelial dysfunction and fibrinolysis insufficiency. Alanine aminotransferase (ALT) may be a sensible marker for the diagnosis of hepatic damage and has therefore been used as an alternative method for the noninvasive diagnosis of non-alcoholic fatty liver disease (NAFLD), especially in epidemiological studies. At the present time, the possible utility of high sensitivity CRP (hsCRP) as a simple measure to detect the degree of hepatic inflammatory response during the development NAFLD in MS has not been explored.
Objective: To evaluate the measurement of serologic hsCRP for the identification of hepatic inflammatory response in patients with MS.
Material and methods: Seven hundred and forty persons (526 men and 214 women), mean age 45 ± 11 years who were asymptomatic and otherwise seeming healthy in whom a medical questionnaire was applied underwent physical examination, laboratory testing, hepatic ultrasound and measurement of hsCRP by the immuno-turbidimetric method. Receiver operating characteristic (ROC) analysis was used to evaluate the sensitivity and specificity of all possible hsCRP for detecting different degrees of hepatic inflammation (ALT › 44 U/L and ALT › 88 U/L). Patients were stratified according to the presence of metabolic syndrome (MS) and ALT concentration in three groups: Group I, having MS and ALT › 44 U/L (n = 39); Group II, having ALT › 44 U/L without MS (n = 105) and Group III, having ALT ≤ 44 U/L without MS (n = 596).
Results: The optimal hs-CRP cut-off for detecting patients with ALT 44 U/L was 2.5 mg/L (sensibility 66%; specificity 50%) and for detecting patients with ALT › 88 U/L was 2.35 (sensibility 72%; specificity 59%). hsCRP serum concentrations in Group I were significantly higher than in Group II and Group III (p ‹ 0.05) but no difference was found between Group II and Group III (Group I = 6.0 ± 6.7 mg/L vs. Group II = 2.8 ± 3.1 mg/L, vs. Group III = 2.9 ± 4.1 mg/L). ALT concentrations were also significantly higher in Group I than in Group II and Group III, (p ‹ 0.05) and a difference between Group II and Group III (p ‹ 0.05) was also found (Group I = 72 ± 31 U/L vs. Group II = 64 ± 29 U/L vs. Group III = 24 ± 8 U/L).
Conclusions: These results suggest that the measurement of hsCRP for the identification of hepatic inflammatory response in patients with MS with NAFLD is limited because of its low sensibility and specificity observed on identifying different degrees of hepatic inflammation.
REFERENCES
Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-31.
Duseja A, Nanda M, Das A, Das R, Bhansali A, Chawla Y. Prevalence of obesity, diabetes mellitus and hyperlipidaemia in patients with cryptogenic liver cirrhosis. Trop Gastroenterol 2004; 25: 15-7.
Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease. A feature of the metabolic syndrome. Diabetes 2001: 1844-50.
Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol 2004; 40: 578-84.
Teli MR, James OFW, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a followup study. Hepatology 1995; 22: 1714-9.
Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up 21 years. Hepatology 1990; 11: 74-80.
Medina J, Fernández-Salazar LI, García-Buey L, Moreno-Otero R. Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes Care 2004; 27: 2057-66.
Castell JV, Andus T, Kunz D, Heinrich PC. Interleukin-6: the major regulator of acute-phase protein sintesis in man and rat. Ann NY Acad Sci 989; 557: 87-101.
Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363-9.
Bassuk SS, Rifai N, Ridker PM. High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol 2004; 29: 439-93.
Daniel S, Ben, Menachem T, Vasudevan G, Ma CK, Blumenkehl M. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol 1999; 94: 3010-4.
The National Cholesterol Education Program: Executive summary of the third report of the NCEP expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel). JAMA 2001; 285: 2486.
Joseph AE, Saverymuttu SH, al-Sam S, Cook MG, Maxwell JD. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol 1991; 43: 26-31.
Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003; 124: 71-9.
Marmot MG, Rose G, Shipley MJ, Thomas BJ. Alcohol and mortality: a U-shaped curve. Lancet 1981; 1: 580.
Ferris B. Epidemiology standarization Project. Annu Rev Resp Dis (Suppl.) 1978; 118: 1.
Bray G. Overweight is risking fate. Definition, classification, prevalence and risks. Ann NY Acad Sci 1987; 499: 14.
Sanchez A, Mirabel JL, Barrenechea E, Eugui J, Puelles A, Castaneda A. Evaluation of an improved immunoturbidimetic assay for serum C-reactive protein on a COBAS INTEGRA 400 Analyzer. Clin Lab 2002; 48: 313-7.
Westhuyzen J, Healy H. Biology and relevance of C-reactive protein in cardiovascular and renal disease. Ann Clin Lab Sci 2000; 30: 133-43.
Du Clor TW. Function of C-reactive protein. Ann Med 2000; 32: 274-8.
Koruk M, Taysi S, Savas MC, Yilmaz O, Akcay F, Karakok M. Serum levels of acute phase proteins in patients with nonalcoholic steatohepatitis. Turk J Gastroenterol 2003; 14: 12-7.
Jeong SK, Nam HS, Rhee JA, Shin JH, Kim JM, Cho KH. Metabolic syndrome and ALT: a community study in adult Koreans. Int J Obesity 2004; 28: 1033-8.
Van Ness MM, Dile AM. Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes? Ann Intern Med 1989; 111: 473-8.
Laurin J. Motion-all patients with NASH need to have a liver biopsy: arguments against the motion. Can J Gastroenterol 2002; 16: 722-6.
Ratzui V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898-906.
De la Mora G, Olivera M, De la Cerda R, Arista J, Kershenobich D, Uribe M. Non-alcoholic fatty liver: 10 year’s experience at the Instituto Nacional de la Nutrición Salvador Zubirán. Rev Invest Clin 1994; 46: 85-92.
Pinol V, Bessa X, Bruguera M, Rodes J. Steatosis and nonalcoholic steatohepatitis. A comparative analysis. Gastroenterol Hepatol 2000; 23: 57-61.
Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-62.
Ratzin V, Giral P, Charlotte F, et al. Liver fibrosis in overweight patients. Gastroenterology 2000; 118: 1117-23.
Luycks FH, Desaive C, Thiry A, et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss alter gastroplasty. Int J Obes Relat Metab Disord 1998; 22: 222-6.
De Ledinghen V, Combes M, Trouette H, et al. Should a liver biopsy be done in patients with subclinical chronically elevated transaminases? Eur J Gastroenterol Hepatol 2004; 16: 879-83.
Full text